Literature DB >> 23980150

Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer.

Yong Peng1, Yuntao Dai, Charles Hitchcock, Xiaojuan Yang, Edmund S Kassis, Lunxu Liu, Zhenghua Luo, Hui-Lung Sun, Ri Cui, Huijun Wei, Taewan Kim, Tae Jin Lee, Young-Jun Jeon, Gerard J Nuovo, Stefano Volinia, Qianchuan He, Jianhua Yu, Patrick Nana-Sinkam, Carlo M Croce.   

Abstract

MicroRNAs (miRNAs) are small 19- to 24-nt noncoding RNAs that have the capacity to regulate fundamental biological processes essential for cancer initiation and progression. In cancer, miRNAs may function as oncogenes or tumor suppressors. Here, we conducted global profiling for miRNAs in a cohort of stage 1 nonsmall cell lung cancers (n = 81) and determined that miR-486 was the most down-regulated miRNA in tumors compared with adjacent uninvolved lung tissues, suggesting that miR-486 loss may be important in lung cancer development. We report that miR-486 directly targets components of insulin growth factor (IGF) signaling including insulin-like growth factor 1 (IGF1), IGF1 receptor (IGF1R), and phosphoinositide-3-kinase, regulatory subunit 1 (alpha) (PIK3R1, or p85a) and functions as a potent tumor suppressor of lung cancer both in vitro and in vivo. Our findings support the role for miR-486 loss in lung cancer and suggest a potential biological link to p53.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23980150      PMCID: PMC3773758          DOI: 10.1073/pnas.1307107110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  miR-486-5p induces replicative senescence of human adipose tissue-derived mesenchymal stem cells and its expression is controlled by high glucose.

Authors:  Yeon Jeong Kim; Soo Hyun Hwang; Sun Young Lee; Keun Koo Shin; Hyun Hwa Cho; Yong Chan Bae; Jin Sup Jung
Journal:  Stem Cells Dev       Date:  2011-11-21       Impact factor: 3.272

2.  MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Priscilla T-Y Law; Arthur K-K Ching; Anthony W-H Chan; Queenie W-L Wong; Chun-Kwok Wong; Ka-Fai To; Nathalie Wong
Journal:  Carcinogenesis       Date:  2012-03-19       Impact factor: 4.944

3.  Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.

Authors:  Rafal Dziadziuszko; Daniel T Merrick; Samir E Witta; Adelita D Mendoza; Barbara Szostakiewicz; Amelia Szymanowska; Witold Rzyman; Katarzyna Dziadziuszko; Jacek Jassem; Paul A Bunn; Marileila Varella-Garcia; Fred R Hirsch
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

4.  Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486.

Authors:  Eric M Small; Jason R O'Rourke; Viviana Moresi; Lillian B Sutherland; John McAnally; Robert D Gerard; James A Richardson; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-08       Impact factor: 11.205

Review 5.  Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy.

Authors:  Cristina E Tognon; Poul H B Sorensen
Journal:  Expert Opin Ther Targets       Date:  2012-01-12       Impact factor: 6.902

6.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Authors:  Zhibin Hu; Xi Chen; Yang Zhao; Tian Tian; Guangfu Jin; Yongqian Shu; Yijiang Chen; Lin Xu; Ke Zen; Chenyu Zhang; Hongbing Shen
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

7.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer.

Authors:  Mattia Boeri; Carla Verri; Davide Conte; Luca Roz; Piergiorgio Modena; Federica Facchinetti; Elisa Calabrò; Carlo M Croce; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

8.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

9.  Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.

Authors:  Daniel D Karp; Michael N Pollak; Roger B Cohen; Peter D Eisenberg; Paul Haluska; Donghua Yin; Allan Lipton; Laurence Demers; Kim Leitzel; Mary L Hixon; Leon W Terstappen; Linda Garland; Luis G Paz-Ares; Felipe Cardenal; Corey J Langer; Antonio Gualberto
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

10.  MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer.

Authors:  S Ali; H Saleh; S Sethi; F H Sarkar; P A Philip
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640

View more
  77 in total

1.  Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection.

Authors:  Maria Sromek; Maciej Glogowski; Magdalena Chechlinska; Mariusz Kulinczak; Lukasz Szafron; Klara Zakrzewska; Joanna Owczarek; Piotr Wisniewski; Robert Wlodarczyk; Lukasz Talarek; Maciej Turski; Jan Konrad Siwicki
Journal:  Cell Oncol (Dordr)       Date:  2017-06-20       Impact factor: 6.730

Review 2.  Statistical analysis of non-coding RNA data.

Authors:  Qianchuan He; Yang Liu; Wei Sun
Journal:  Cancer Lett       Date:  2018-01-04       Impact factor: 8.679

Review 3.  A network-biology perspective of microRNA function and dysfunction in cancer.

Authors:  Cameron P Bracken; Hamish S Scott; Gregory J Goodall
Journal:  Nat Rev Genet       Date:  2016-10-31       Impact factor: 53.242

4.  Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study.

Authors:  Xin Wang; Xiuyi Zhi; Yi Zhang; Guangyu An; Guosheng Feng
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

5.  MicroRNAs hsa-miR-495-3p and hsa-miR-486-5p suppress basal and rifampicin-induced expression of human sulfotransferase 2A1 (SULT2A1) by facilitating mRNA degradation.

Authors:  Dongying Li; Bridgett Knox; Si Chen; Leihong Wu; William H Tolleson; Zhichao Liu; Dianke Yu; Lei Guo; Weida Tong; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2019-08-22       Impact factor: 5.858

6.  Network-based analysis implies critical roles of microRNAs in the long-term cellular responses to gold nanoparticles.

Authors:  Priscila Falagan-Lotsch; Catherine J Murphy
Journal:  Nanoscale       Date:  2020-09-29       Impact factor: 7.790

7.  Selective targeting of alveolar type II respiratory epithelial cells by anti-surfactant protein-C antibody-conjugated lipoplexes.

Authors:  Yun Wu; Junyu Ma; Parker S Woods; Nicholas M Chesarino; Chang Liu; L James Lee; Serge P Nana-Sinkam; Ian C Davis
Journal:  J Control Release       Date:  2015-02-14       Impact factor: 9.776

8.  MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc.

Authors:  Rana Ahmed Youness; Hend Mohamed El-Tayebi; Reem Amr Assal; Karim Hosny; Gamal Esmat; Ahmed Ihab Abdelaziz
Journal:  Oncol Lett       Date:  2016-07-27       Impact factor: 2.967

9.  Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer.

Authors:  Wenqiang Song; Laura C Kim; Wei Han; Yuan Hou; Deanna N Edwards; Shan Wang; Timothy S Blackwell; Feixiong Cheng; Dana M Brantley-Sieders; Jin Chen
Journal:  Mol Cancer Res       Date:  2020-08-04       Impact factor: 5.852

10.  MiR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R.

Authors:  Xiaoli Wang; Yuchang Wang; Hongwen Lan; Jun Li
Journal:  Tumour Biol       Date:  2014-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.